Clinical Trial Detail

NCT ID NCT04214860
Title APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Aprea Therapeutics AB
Indications

acute myeloid leukemia

Therapies

APR-246 + Azacitidine + Venetoclax

Age Groups: adult senior

No variant requirements are available.